Cortechs.ai Gets FDA Clearance for NeuroQuant PET
Cortechs.ai announced in a press release that NeuroQuant PET received U.S. Food and Drug Administration (FDA) 510(k) clearance for PET. The software aids physicians in evaluating patient pathologies and interpreting PET studies for cognitive impairment and other neurological conditions.
NeuroQuant PET provides automated quantification, regional analysis, and structured reporting for clinical workflows. It supports amyloid PET tracers including flutemetamol, florbetaben, and florbetapir, and generates standardized uptake value ratios and Centiloid measurements.
The platform supports PET CT, PET MR, and PET only workflows. It segments regions of interest and creates outputs prepared for PACS integration.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 9 Assort Health and Nextech to Build AI Agent for Ophthalmology Practices Oct 9 PhyPal Relaunches Patient Engagement Platform With Conversational AI Oct 9 Helio Genomics Presents Four HelioLiver Studies on Liver Cancer Detection Oct 8 GenScript and NVIDIA Open Life Sciences AI Startup PitchFest Oct 8 Xtalks Plans Webinar on AI for Antibody Process OptimizationLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Quantiphi Named Leader in NelsonHall Wealth Management Evaluation
FDA Clears Nutshell Therapeutics' NRF2 Degrader NTS231
HOPPR Brings Radiology Foundation Models to CARPL.ai
Aignostics Opens Early Access to PathoSearch
Phylo Launches Target Atlas for Drug Target Prioritization
Daily AI Brief: the AI news that matters, in your inbox.